{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T22:20:58Z","timestamp":1767824458316,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T00:00:00Z","timestamp":1112313600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T00:00:00Z","timestamp":1112313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Background<\/jats:title>\n                        <jats:p>Naltrexone is an effective medication for treatment of alcohol dependence, but its efficacy is limited by lack of adherence to the oral dosage form. A long-acting depot formulation of naltrexone may increase adherence.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>A single site, 6-week open label study was conducted with 16 alcohol dependent subjects each receiving 300 mg of Naltrexone Depot by intramuscular injection. The main outcomes were safety and tolerability of the Naltrexone Depot formulation, blood levels of naltrexone and its main metabolite 6-beta naltrexol, and self-reported alcohol use. All subjects received weekly individual counseling sessions.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>The medication was well tolerated with 88% of subjects completing the 6-week trial. The most common side effect experienced was injection site complications. There were no serious adverse events. Subjects had naltrexone and 6-beta-naltrexol concentrations throughout the trial with mean values ranging from 0.58 ng\/mL to 2.04 ng\/mL and 1.51 ng\/mL to 5.52 ng\/mL, respectively, at each sampling time following administration. Compared to baseline, subjects had significantly reduced number of drinks per day, heavy drinking days and proportion of drinking days.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusion<\/jats:title>\n                        <jats:p>Naltrexone Depot is safe and well tolerated in alcoholics and these findings support the further investigation of its utility in larger double-blind placebo controlled trials.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/1471-244x-5-18","type":"journal-article","created":{"date-parts":[[2005,4,2]],"date-time":"2005-04-02T06:14:11Z","timestamp":1112422451000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial"],"prefix":"10.1186","volume":"5","author":[{"given":"Gantt P","family":"Galloway","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Koch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Cello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David E","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,4,1]]},"reference":[{"key":"100_CR1","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/archpsyc.1992.01820110045007","volume":"49","author":"SS O'Malley","year":"1992","unstructured":"O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsville B: Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry. 1992, 49: 881-887.","journal-title":"Arch Gen Psychiatry"},{"key":"100_CR2","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1001\/archpsyc.1992.01820110040006","volume":"49","author":"JR Volpicelli","year":"1992","unstructured":"Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP: Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992, 49: 876-880.","journal-title":"Arch Gen Psychiatry"},{"key":"100_CR3","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1097\/01.ALC.0000075548.83053.A9","volume":"27","author":"J Balldin","year":"2003","unstructured":"Balldin J, Berglund M, Borg S, Mansson M, Bendtsen P, Franck J, Gustafsson L, Halldin J, Nilsson LH, Stolt G, Willander A: A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res. 2003, 27: 1142-1149. 10.1097\/01.ALC.0000075548.83053.A9.","journal-title":"Alcohol Clin Exp Res"},{"key":"100_CR4","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1176\/ajp.156.11.1758","volume":"156","author":"RF Anton","year":"1999","unstructured":"Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK: Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry. 1999, 156: 1758-1764.","journal-title":"Am J Psychiatry"},{"key":"100_CR5","first-page":"1074","volume":"22","author":"HR Kranzler","year":"1998","unstructured":"Kranzler HR, Modesto-Lowe V, Nuwayser ES: Sustained-release naltrexone for alcoholism treatment: a preliminary study. Alcohol Clin Exp Res. 1998, 22: 1074-1079.","journal-title":"Alcohol Clin Exp Res"},{"key":"100_CR6","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/j.1530-0277.1996.tb01679.x","volume":"20","author":"D Davidson","year":"1996","unstructured":"Davidson D, Swift R, Fitz E: Naltrexone increases the latency to drink alcohol in social drinkers. Alcohol Clin Exp Res. 1996, 20: 732-739.","journal-title":"Alcohol Clin Exp Res"},{"key":"100_CR7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1530-0277.1999.tb04099.x","volume":"23","author":"D Davidson","year":"1999","unstructured":"Davidson D, Palfai T, Bird C, Swift R: Effects of naltrexone on alcohol self-administration in heavy drinkers. Alcohol Clin Exp Res. 1999, 23: 195-203.","journal-title":"Alcohol Clin Exp Res"},{"key":"100_CR8","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1176\/ajp.151.10.1463","volume":"151","author":"RM Swift","year":"1994","unstructured":"Swift RM, Whelihan W, Kuznetsov O, Buongiorno G, Hsuing H: Naltrexone-induced alterations in human ethanol intoxication. Am J Psychiatry. 1994, 151: 1463-1467.","journal-title":"Am J Psychiatry"},{"key":"100_CR9","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1111\/j.1530-0277.2001.tb02356.x","volume":"25","author":"HR Kranzler","year":"2001","unstructured":"Kranzler HR, Van Kirk J: Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res. 2001, 25: 1335-1341. 10.1097\/00000374-200109000-00014.","journal-title":"Alcohol Clin Exp Res"},{"key":"100_CR10","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1093\/alcalc\/36.6.544","volume":"36","author":"C Streeton","year":"2001","unstructured":"Streeton C, Whelan G: Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol. 2001, 36: 544-552.","journal-title":"Alcohol Alcohol"},{"issue":"6","key":"100_CR11","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1093\/alcalc\/36.6.544","volume":"36","author":"JH Krystal","year":"2001","unstructured":"Krystal JH, Cramer JA, Krol WF, Kirk GF, Roseheck RA: Naltrexone in the treatment of alcohol dependence: a meta-analysis of randemized controlled trials. Alcohol Alcohol. 2001, 36 (6): 544-552.","journal-title":"Alcohol Alcohol"},{"key":"100_CR12","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1097\/00004714-200212000-00009","volume":"22","author":"M Gastpar","year":"2002","unstructured":"Gastpar M, Bonnet U, Boning J, Mann K, Schmidt LG, Soyka M, Wetterling T, Kielstein V, Labriola D, Croop R: Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J Clin Psychopharmacol. 2002, 22: 592-598. 10.1097\/00004714-200212000-00009.","journal-title":"J Clin Psychopharmacol"},{"key":"100_CR13","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0893-133X(99)00135-9","volume":"22","author":"HR Kranzler","year":"2000","unstructured":"Kranzler HR, Modesto-Lowe V, Van Kirk J: Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsychopharmacology. 2000, 22: 493-503. 10.1016\/S0893-133X(99)00135-9.","journal-title":"Neuropsychopharmacology"},{"key":"100_CR14","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.3109\/10826089609063965","volume":"31","author":"J Chick","year":"1996","unstructured":"Chick J: The efficacy of treatments in reducing alcohol consumption: a meta-analysis. Subst Use Misuse. 1996, 31: 1081-","journal-title":"Subst Use Misuse"},{"key":"100_CR15","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1001\/archpsyc.1997.01830200071010","volume":"54","author":"JR Volpicelli","year":"1997","unstructured":"Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP: Naltrexone and alcohol dependence. Role of subject compliance. Arch Gen Psychiatry. 1997, 54: 737-742.","journal-title":"Arch Gen Psychiatry"},{"key":"100_CR16","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1001\/jama.1986.03380110055026","volume":"256","author":"RK Fuller","year":"1986","unstructured":"Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, James KE, Lacoursiere RB, Lee KK, Lowenstam I, et al: Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. Jama. 1986, 256: 1449-1455. 10.1001\/jama.256.11.1449.","journal-title":"Jama"},{"key":"100_CR17","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1530-0277.1996.tb01647.x","volume":"20","author":"WM Cox","year":"1996","unstructured":"Cox WM, Blount JP, Crowe PA, Singh SP: Diabetic patients' alcohol use and quality of life: relationships with prescribed treatment compliance among older males. Alcohol Clin Exp Res. 1996, 20: 327-331.","journal-title":"Alcohol Clin Exp Res"},{"key":"100_CR18","first-page":"13","volume":"45","author":"DA Johnson","year":"1984","unstructured":"Johnson DA: Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia. J Clin Psychiatry. 1984, 45: 13-21.","journal-title":"J Clin Psychiatry"},{"key":"100_CR19","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s002130100909","volume":"159","author":"SD Comer","year":"2002","unstructured":"Comer SD, Collins ED, Kleber HD, Nuwayser ES, Kerrigan JH, Fischman MW: Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psychopharmacology (Berl). 2002, 159: 351-360. 10.1007\/s002130100909.","journal-title":"Psychopharmacology (Berl)"},{"key":"100_CR20","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1053\/gn.1999.v20.103922001","volume":"20","author":"G Kaempf","year":"1999","unstructured":"Kaempf G, O'Donnell C, Oslin DW: The BRENDA model: a psychosocial addiction model to identify and treat alcohol disorders in elders. Geriatr Nurs. 1999, 20: 302-304. 10.1053\/gn.1999.v20.103922001.","journal-title":"Geriatr Nurs"},{"key":"100_CR21","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1300\/J069v19n01_06","volume":"19","author":"HM Pettinati","year":"2000","unstructured":"Pettinati HM, Volpicelli JR, Pierce JDJ, O'Brien CP: Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. J Addict Dis. 2000, 19: 71-83. 10.1300\/J069v19n01_06.","journal-title":"J Addict Dis"},{"key":"100_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/978-1-4612-0357-5_3","volume-title":"Measuring Alcohol Consumption","author":"LC Sobell","year":"1992","unstructured":"Sobell LC, Sobell MB: Timeline follow-back: a technique for assessing self-reported alcohol consumption. Measuring Alcohol Consumption. Edited by: Litten R and Allen J. 1992, Clifton, N.J., The Humana Press, Inc., 41-72."},{"key":"100_CR23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/0306-4603(86)90040-7","volume":"11","author":"MB Sobell","year":"1986","unstructured":"Sobell MB, Sobell LC, Klajner F, Pavan D, Basian E: The reliability of a timeline method for assessing normal drinker college students' recent drinking history: utility for alcohol research. Addict Behav. 1986, 11: 149-161. 10.1016\/0306-4603(86)90040-7.","journal-title":"Addict Behav"},{"key":"100_CR24","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/j.1360-0443.1988.tb00485.x","volume":"83","author":"LC Sobell","year":"1988","unstructured":"Sobell LC, Sobell MB, Leo GI, Cancilla A: Reliability of a timeline method: assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations. Br J Addict. 1988, 83: 393-402.","journal-title":"Br J Addict"},{"key":"100_CR25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/0376-8716(96)01263-X","volume":"42","author":"LC Sobell","year":"1996","unstructured":"Sobell LC, Brown J, Leo GI, Sobell MB: The reliability of the Alcohol Timeline Followback when administered by telephone and by computer. Drug Alcohol Depend. 1996, 42: 49-54. 10.1016\/0376-8716(96)01263-X.","journal-title":"Drug Alcohol Depend"},{"key":"100_CR26","first-page":"15","volume":"45","author":"MC Meyer","year":"1984","unstructured":"Meyer MC, Straughn AB, Lo MW, Schary WL, Whitney CC: Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. J Clin Psychiatry. 1984, 45: 15-19.","journal-title":"J Clin Psychiatry"},{"key":"100_CR27","first-page":"369","volume":"9","author":"ME Wall","year":"1981","unstructured":"Wall ME, Brine DR, Perez-Reyes M: Metabolism and disposition of naltrexone in man after oral and intravenous administration. Drug Metab Dispos. 1981, 9: 369-375.","journal-title":"Drug Metab Dispos"},{"key":"100_CR28","first-page":"506","volume":"2","author":"EJ Cone","year":"1974","unstructured":"Cone EJ, Gorodetzky CW, Yeh SY: The urinary excretion profile of naltrexone and metabolites in man. Drug Metab Dispos. 1974, 2: 506-512.","journal-title":"Drug Metab Dispos"},{"key":"100_CR29","first-page":"xxi, 1905 p.","volume-title":"Goodman & Gilman's the pharmacological basis of therapeutics","author":"LS Goodman","year":"1996","unstructured":"Goodman LS, Gilman A, Hardman JG, Gilman AG, Limbird LE, Molinoff PB, Ruddon RW: Goodman & Gilman's the pharmacological basis of therapeutics. 1996, New York, McGraw-Hill, Health Professions Division, xxi, 1905 p.-9th","edition":"9th"},{"key":"100_CR30","first-page":"214","volume":"28","author":"KR Sidman","year":"1981","unstructured":"Sidman KR, Schwope AD, Steber WD, Rudolph SE: Use of synthetic polypeptides in the preparation of biodegradable delivery systems for narcotic antagonists. NIDA Res Monogr. 1981, 28: 214-231.","journal-title":"NIDA Res Monogr"},{"key":"100_CR31","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1111\/j.1530-0277.2002.tb02682.x","volume":"26","author":"J Guardia","year":"2002","unstructured":"Guardia J, Caso C, Arias F, Gual A, Sanahuja J, Ramirez M, Mengual I, Gonzalvo B, Segura L, Trujols J, Casas M: A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial. Alcohol Clin Exp Res. 2002, 26: 1381-1387. 10.1097\/00000374-200209000-00011.","journal-title":"Alcohol Clin Exp Res"},{"key":"100_CR32","first-page":"187","volume":"28","author":"JL Olsen","year":"1981","unstructured":"Olsen JL, Kincl FA: A review of parenteral sustained-release naltrexone systems. NIDA Res Monogr. 1981, 28: 187-193.","journal-title":"NIDA Res Monogr"},{"key":"100_CR33","first-page":"906","volume":"21","author":"AC King","year":"1997","unstructured":"King AC, Volpicelli JR, Gunduz M, O'Brien CP, Kreek MJ: Naltrexone biotransformation and incidence of subjective side effects: a preliminary study. Alcohol Clin Exp Res. 1997, 21: 906-909.","journal-title":"Alcohol Clin Exp Res"},{"key":"100_CR34","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3109\/00952997509005661","volume":"2","author":"K Verebey","year":"1975","unstructured":"Verebey K, Mule SJ: Naltrexone pharmacology, pharmacokinetics, and metabolism: current status. Am J Drug Alcohol Abuse. 1975, 2: 357-363.","journal-title":"Am J Drug Alcohol Abuse"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-5-18.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/1471-244X-5-18\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-5-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-5-18.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T12:53:00Z","timestamp":1728305580000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/1471-244X-5-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4,1]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2005,12]]}},"alternative-id":["100"],"URL":"https:\/\/doi.org\/10.1186\/1471-244x-5-18","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,4,1]]},"assertion":[{"value":"5 October 2004","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2005","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2005","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"18"}}